Condition: Extensive-stage Small-cell Lung Cancer · Sponsor: Second Hospital of Shanxi Medical University
This study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive stage small cell lung cancer.
This description comes directly from the study's public registry record.
Gang Jin, Dr. · +86 351 3365422 · jingang2018@sina.com
Chen Zhang · +86 351 3365422 · jingang2018@sina.com
Always discuss trial participation with your own doctor first.
| Jincheng General Hospital | Jincheng, Shanxi, China | Recruiting |
| Jinzhong third people's hospital | Jinzhong, Shanxi, China | Recruiting |
| Second Hospital of Shanxi Medical University | Taiyuan, Shanxi, China | Recruiting |
| Shanxi Bethune Hospital | Taiyuan, Shanxi, China | Recruiting |
| Shanxi Hospital of Traditional Chinese Medicine | Taiyuan, Shanxi, China | Recruiting |
| TISCO General Hospital | Taiyuan, Shanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06536868